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A B S T R A C T
Toll-like receptor (TLR) agonists can effectively stimulate antigen-presenting cells (APCs) and are anticipated to
be promising adjuvants in combination with inactivated vaccines. In this study, the adjuvant potential of three
different TLR-agonists were compared with an oil-in-water (O/W) adjuvant in combination with inactivated
porcine reproductive and respiratory syndrome virus (iPRRSV) applied by different administration routes: in-
tramuscular (i.m.) or into the skin using dissolving microneedle (DMN) patches. Pigs received a prime vacci-
nation followed by a booster vaccination four weeks later. TLR1/2 (Pam3Cys), TLR7/8 (R848) or TLR9 (CpG
ODN) agonists were used as adjuvant in combination with iPRRSV strain 07V063. O/W adjuvant (Montanide™)
was used as reference control adjuvant and one group received a placebo vaccination containing diluent only. All
animals received a homologous challenge with PRRSV three weeks after the booster vaccination. Antibody and
IFN-γ production, serum cytokines and viremia were measured at several time-points after vaccination and/or
challenge, and lung pathology at necropsy. Our results indicate that a TLR 1/2, 7/8 or 9 agonist as adjuvant with
iPRRSV does not induce a detectable PRRSV-specific immune response, independent of the administration route.
However, the i.m. TLR9 agonist group showed reduction of viremia upon challenge compared to the non-vac-
cinated animals, supported by a non-antigen-specific IFN-γ level after booster vaccination and an anamnestic
antibody response after challenge. Montanide™-adjuvanted iPRRSV induced antigen-specific immunity after
booster combined with reduction of vireamia. Skin application of TLR7/8 agonist, but not the other agonists,
induced a local skin reaction. Further research is needed to explore the potential of TLR agonists as adjuvants for
inactivated porcine vaccines with a preference for TLR9 agonists.
1. Introduction
Porcine reproductive and respiratory syndrome (PRRS) is an im-
portant viral disease affecting swine health and welfare. The swine
industry reports large economic losses due to the PRRS virus (PRRSV)
(Nathues et al., 2017; Nieuwenhuis et al., 2012) and vaccination is
essential to prevent PRRSV infection and transmission. The disease is
widespread globally, and after infection there is a variable morbidity
and mortality with reproductive disorders in sows and respiratory
symptoms often with co-infections in growing and finishing pigs.
PRRSV is an enveloped, positive-stranded RNA virus of the
Arteriviridae family of which two distinct viral species are known (King
et al., 2018): PRRSV-1, most relevant in Europe and divided in three
subtypes (Stadejek et al., 2008) with a different pathogenicity, and
PRRSV-2, mostly occurring in North America and South East Asia (Brar
et al., 2015; Nelsen et al., 1999). PRRSV-1 and PRRSV-2 are constantly
evolving and new strains appear, which complicates the development of
a protective vaccine (Kappes and Faaberg, 2015). Several commercial
vaccines have been licenced for the different types of PRRSV (Nan et al.,
2017). In general, modified-live-virus vaccines induce a good protec-
tion against homologous infections, however cross protection and
safety are points of concern (Renukaradhya et al., 2015). Conversely,
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inactivated PRRSV (iPRRSV) vaccines are safe to use, but provide
limited protection (Geldhof et al., 2012; Renukaradhya et al., 2015;
Vanhee et al., 2009; Zuckermann et al., 2007). Safe and effective
iPRRSV vaccines are needed for virus control and adjuvants such as
Toll-like receptor (TLR) agonists could help to increase the vaccine
efficacy.
TLRs are a family of conserved pattern recognition receptors (PRRs)
that recognize specific parts of microbial pathogens and activation of
these receptors links the innate and adaptive immune response by ac-
tivation of APCs (Takeda and Akira, 2005). Vaccines can benefit from
this property by using specific synthetic TLR agonists (TLRa) as ad-
juvant to increase the magnitude and the efficacy of the immune re-
sponse (Maisonneuve et al., 2014). TLRa have been extensively in-
vestigated in mice and humans for their immunostimulatory properties
(Steinhagen et al., 2011; Toussi and Massari, 2014) and their applica-
tions as adjuvants. However, functional differences of specific TLRs and
variation between species (Akira and Takeda, 2004; Uenishi and
Shinkai, 2009) necessitates investigation of the efficacy of individual
TLRa in porcine vaccines. in vitro stimulation of various porcine TLRs
demonstrated that predominantly TLR2a, 7a and 9a (Auray et al., 2016;
Vreman et al., 2018) induced activation of APCs, which is important for
antigen uptake and transport to the draining lymph nodes. Also in vivo,
individual administration of TLR2a (Basto and Leitao, 2014), 7a or 9a
(Scheiermann and Klinman, 2014; Steinhagen et al., 2011; Van der
Stede et al., 2002) enhanced the quality and quantity of the host
adaptive immune response in several vaccine studies in humans and
mice. Therefore, TLR2a, 7a and 9a are interesting candidates as ad-
juvants for iPRRSV vaccine development.
The search for an optimal antigen-adjuvant combination is a critical
step in the development of inactivated vaccines (Knudsen et al., 2016).
TLRa have been previously studied in combination with PRRSV-2.
CL097, a TLR7a, combined with iPRRSV-2 enhanced the immune re-
sponse and protection against PRRSV in pigs (Zhang et al., 2013), and
the effect could be mimicked in mice by using the TLR7a SZU101
combined with PRRSV-2 (Du et al., 2016). Other porcine studies have
shown that iPRRSV-2 in combination with a TLR9a (CpG ODN) en-
hanced protection after challenge with a highly pathogenic PRRSV-2
strain (Linghua et al., 2007; Quan et al., 2010). To our knowledge,
TLR2a have not been used in recent PRRSV vaccination research. In this
study we focussed on PRRSV-1, which is most common in Western
Europe and is known to have large genomic differences compared to
PRRSV-2 (Stadejek et al., 2013).
Additionally to the use of adjuvants, the route of administration can
be crucial to achieve optimal protection after vaccination. Different
delivery routes with the same vaccine can induce variation in immune
response and efficacy (Vrdoljak et al., 2016; Zhang et al., 2015). The
efficacy of TLR9a CpG ODN with live-attenuated PRRSV vaccine was
route-dependent: i.m. administration reduced the viral shedding more
than the intranasal route (Ouyang et al., 2016). The magnitude of the
immune response and the cytokine profile were differentially affected
using intradermal or intranasal vaccination routes in a mouse model
with a TLR7/8a (R848) as adjuvant (van Aalst et al., 2018). Dissolving
microneedle (DMN) patches deliver the vaccine directly into the skin
and possibly thereby target high numbers of APCs that are con-
stitutively present in the skin. Skin-based vaccination may thus result in
equivalent or stronger immune responses compared to traditional i.m or
subcutaneous routes (Ferrari et al., 2013; Marshall et al., 2016), espe-
cially when combined with appropriate adjuvants (Krejci et al., 2013).
Other reported advantages of skin vaccination are dose reduction (Eble
et al., 2009) and generation of mucosal immune responses, which is
especially important for respiratory diseases (Le Luduec et al., 2016;
Martelli et al., 2014). Previous studies with TLRa showed that in-
tradermal injection of TLR9a in pigs may promote recruitment of innate
immune cells and Th1 cytokine production (Magiri et al., 2016), while a
TLR7a can augment antigen-specific serum responses in mini-pigs
(McKay et al., 2016). Overall, the skin seems a promising administra-
tion site to combine with TLRa in iPRRSV vaccines. However, to our
knowledge, no studies to date have evaluated the microneedle-based
skin delivery of TLRa to non-mouse species (Weldon et al., 2012).
In this study we investigated the immunogenicity and efficacy of
TLR1/2a (Pam3Cys), TLR7/8a (R848) or TLR9a (CpG ODN) as adjuvant
with iPRRSV-1 administered by i.m. injection or skin-based DMN pat-
ches. The antigen-specific PRRSV antibody response, IFN-γ production,
reduction of viremia, serum cytokines and lung pathology after chal-
lenge were assessed to define the immune responses of the pigs.
2. Material and methods
2.1. Virus
PRRSV strain Belgium A (07V063) is a low pathogenic subtype 1
PRRSV-1 isolate. This strain was isolated from an aborted foetus from a
Belgian farm, by inoculation of porcine alveolar macrophages (PAM)
(Van Doorsselaere et al., 2011). This strain was used in recent studies
describing viral, clinical and pathological data (Karniychuk et al., 2010;
Weesendorp et al., 2013) and as inactivated virus for vaccination
(Geldhof et al., 2012).
For challenge, MARC-Sn grown stocks were prepared of the isolates
07V063 (4th passage on MARC-Sn cells). For vaccine preparation,
MARC-Sn cell culture supernatants of 07V063 (2nd passage on
PAM+2 passages on MARC-Sn), were purified via ultracentrifugation
as described previously (Vanhee et al., 2009).
2.2. Virus inactivation and quality control
Purified virus (07V063) was suspended in RPMI 1640 (Invitrogen)
to a titer of 10 9.7 TCID50/mL. Subsequently, the virus was inactivated
using binary ethylenimine (BEI) as described before (Vanhee et al.,
2009), and inactivated virus was stored at −80 °C. To confirm that all
virus was completely inactivated, a complete vaccine dose of 07V063
was inoculated on MARC-145 cells and subsequently passaged twice. As
a positive control, MARC-145 cells were inoculated with 1ml of non-
inactivated 07V063. The MARC-145 cells were routinely checked for
cytopathic effect (CPE) and ultimately stained for the PRRSV nucleo-
capsid protein via an immunoperoxidase monolayer assay (IPMA) using
monoclonal antibody 13E2 (Van Breedam et al., 2011). No CPE or
positive nucleocapsid staining was detected in cells that were in-
oculated with inactivated virus, while clear CPE and nucleocapsid
staining were observed in cell cultures that were inoculated with non-
inactivated virus. Since conservation of entry of inactivated virus may
serve as a quality control for the preservation of antigenic properties,
the effect of BEI inactivation on virus attachment and internalization
into macrophages was examined as described previously (Vanhee et al.,
2009). Non-inactivated virus suspensions were included as positive
controls. The entry experiment showed that the binding and inter-
nalization kinetics of all BEI-inactivated virus stocks are similar to those
observed for the non-inactivated virus stocks.
2.3. Vaccines
All the vaccines (i.m. and DMN-patches) contained the same dose of
BEI-inactivated PRRSV 07V063 (1.0×108.0TCID50) with different ad-
juvants. Montanide™ ISA 28 R VG (kindly provided by SEPPIC), an oil-
in-water (O/W) emulsion compromising a blend of a mineral and non-
mineral oil, was selected as reference control adjuvant, as a previous
study with PRRSV 07V063 (Geldhof et al., 2012) showed a clear anti-
body response with a similar O/W adjuvant. Montanide™ was ad-
ministered only i.m., as 15% volume per volume (v/v) in a final volume
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of 1ml according to manufacturer’s instruction. The adjuvants of the
experimental groups were composed of different TLRa: TLR1/2a;
Pam3Cys L2000 from EMC micro-collections, TLR7/8a; R848, Re-
siquimod from InvivoGen or TLR9a; CpG ODN-type A sequence D32, 5′-
ggTGCGTCGACGCAGggggg-3′, from Eurofins Genomics (Auray et al.,
2016; Vreman et al., 2018). All vaccines (i.m. and DMN-patches) con-
tained 250 μg of the individual TLRa (Fig. 1b). This adjuvant dose was
based on study results, which were obtained in different animal species
and using different delivery routes, for Pam3Cys (Shakya et al., 2011),
R848 (McKay et al., 2016; Salabert et al., 2016), CpG ODN (Linghua
et al., 2006; Quan et al., 2010) and the maximum dose which could be
incorporated in the DMN- patches. The i.m. vaccines were freshly
prepared on the day of vaccination and mixed with PBS to a volume of
1ml.
Each DMN patch contained 225 microneedles, 500 μm in length, in
a 9 cm2 area. They were prepared as previously described (Vrdoljak
et al., 2016), using trehalose and polyvinyl alcohol (PVA) as excipients.
The iPRRSV and TLRa was dispersed homogenously throughout the full
volume of the microneedle. Briefly, formulation was delivered directly
onto the water-filled microneedle cavities in a polydimethylsiloxane
(PDMS) mould at a rate of 1–3 μL/min. Formulation in the moulds was
dried overnight at room temperature and then pulled from the mould
onto medical grade adhesive tape (1525 l Poly Med tape, 3M). The
patches were immediately packaged and sealed in moisture-barrier
bags containing desiccant and stored at 2–8 °C prior to shipping and
administration.
2.4. Animals and housing
Forty-eight (n=48) male six-week-old pigs (Topigs Norsvin Z-line,
commercial breed) were purchased from a PRRSV-negative, high health
status farm (van Beek SPF Varkens B.V.) in the Netherlands. The ser-
onegative-PRRSV status of the pigs was confirmed upon arrival at the
research facility with a commercial antibody ELISA. After arrival, the
pigs were stratified based on their weight and family background fol-
lowed by a randomisation to eight groups (n=6 for each group).
Before challenge the animals were housed in eight separated boxes in
one stable. One week before challenge the animals were moved to 8
separate rooms in an isolation unit with HEPA-filtered air. All the
stables were enriched with straw and toys. Standard feed for finishing
pigs was provided twice a day and the pigs had unlimited access to
water. The experiment started after one week of acclimatization. The
animal experiment was conducted in accordance with the Dutch animal
experimental and ethical requirements and the project license appli-
cation was approved by the Dutch Central Authority for Scientific
Procedures on Animals (CCD) (Permit number: ADV401002015356).
2.5. Experimental design
All the pigs except for the non-vaccinated (NV) group received a
prime vaccination (D0) with iPRRSV and different adjuvants (Fig. 1A
and B) at 7 weeks of age followed by a booster vaccination (D28) at 11
weeks of age. The NV control group received 1.0 ml of PBS i.m. in the
right hind leg. The reference control group (O/W con) group received
O/W adjuvant Montanide® i.m. (1.0ml) in the right hind leg. The six
experimental groups with the different TLR agonists were divided in
three i.m groups (imTLR1/2a, 7/8a and 9a) and three groups with
DMN-patches (skiTLR1/2a, 7/8a and 9a).
The lateral right hind leg was used for the i.m. injection (1.0ml) and
the DMN-patch was applied at the medial side of the left hind leg.
Before vaccination with a DMN-patch the pigs were sedated i.m. with a
mixture of Zoletil® (4 mg/kg, Virbac) and Sedamun® (2 mg/kg, Dechra)
to ensure correct and equal application and by this optimize standar-
disation of skin vaccination. Pigs receiving an i.m vaccination were not
sedated. The DMN-patches were removed after 24 h. Three weeks after
the booster vaccination (D49; 14 weeks of age) all animals were chal-
lenged intranasally with PRRSV 07V063 (106 TCID50) in PBS (1.0ml
per nostril). Three weeks post challenge (D70) the animals were eu-
thanized with pentobarbital (150mg/kg intravenous) after i.m. seda-
tion with a mixture of Zoletil® (4 mg/kg, Virbac) and Sedamun® (2 mg/
kg, Dechra), followed by exsanguination. During necropsy different
lung lobes were collected for pathological examination.
2.6. Monitoring of post-vaccination and challenge reaction
After vaccination the injection site or DMN-patch application area
were monitored over 4 days for local effects, such as redness and
swelling of skin, graded from 0 (no changes) to 3 (clear redness and
swelling of skin). Rectal temperature and clinical signs were recorded
daily from two days before vaccination until 4 days after vaccination,
and twice a day from one week before challenge until the end of the
experiment respectively. Fever was defined as body temperature higher
than 40 °C. Pigs were monitored twice a day for PRRSV-related clinical
signs: liveliness, coughing, breathing, skin changes ears and appetite, as
previously described (Weesendorp et al., 2013). Pigs were weighed
upon arrival (D-7), three weeks after booster vaccination (D48) and
during the challenge (D56, D63 and D70).
2.7. Blood sample collection and pre-treatment
Serum samples were collected at D-4, D21, D28, D35, D42, D48,
D52, D54, D57, D59, D63 and D66 to determine virus titres and anti-
body levels. Serum samples from D52 (3 days after challenge) were
Fig. 1. Experimental design and group over-
view. (A) Study design with prime vaccination
at D0, booster vaccination at D28 followed by a
homologous challenge at D49 and necropsy at
D70; (B) Group overview: non-vaccinated ani-
mals (NV); in all vaccinated groups iPRRSV
07V063 antigen was used either with
Montanide ™ ISA 28R VG (O/W con) or Toll-
like receptor agonist (TLR1/2a, TLR7/8a or
TLR9a); im, indicates groups with i.m. vacci-
nation; ski indicates groups with skin vacci-
nation with dissolving microneedle (DMN)-
patch.
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used for cytokine determination. The samples were stored directly at
−80 °C until analysis.
Heparin stabilized blood samples (approximately 15ml) were col-
lected at D21 and D42 for isolation of PBMCs for IFN-γ ELISpot assay.
Collected blood was diluted 1:1 with PBS within 2 h of collection and
transferred to a Leucosep® tube using a 60% FICOLL-PAQUE™ Plus
density- gradient to isolate the PBMCs. Remaining red blood cells were
lysed with ACK lysis buffer. PBMC were rested overnight at 4 °C before
further analysis or freezing. Additionally, on D-4 we collected whole
blood samples in Paxgene® RNA tubes for future analysis on genetic
markers.
2.8. PRRSV serology
Serum samples were thawed on ice and the PRRSV-specific IgG
antibodies in serum samples were tested with an indirect antibody
ELISA (IDEXX PRRS X3 enzyme immunoassay) designed to detect
PRRSV IgG antibodies using a recombinant nucleocapsid (N) protein as
the coating antigen and an anti-pig immunoglobulin (Ig)G-HRP con-
jugate in a second step (Diaz et al., 2012). The kit was used according to
the manufacturer’s instruction and a sample-to-positive ratio of equal or
greater than 0.4 was considered positive. Samples that tested negative
were consequently given a numerical value of 0.00.
2.9. IFN-γ ELISpot assay
The number of antigen-specific IFN-γ secreting cells (SCs) was de-
termined with an enzyme-linked immunospot assay) ELISpot assay kit
(Porcine IFN-γ ELISpot PLUS (ALP) from Mabtech) according to the
manufacturer’s instruction. Briefly, 0.5× 106 PBMCs were added to
antibody pre-coated 96 well plates in RPMI 1640 medium (Gibco®)
supplemented with 10% FBS and 1% Penicillin-Streptomycin (Gibco®).
Cells were stimulated with PRRSV 07V063 with a multiplicity of in-
fection (MOI) of 0.1 based on previous ELIspot results with PRSSV-1
stimulation (Mair et al., 2015; Mokhtar et al., 2016; Weesendorp et al.,
2013). Cells without stimulus (medium only) were used as negative
control. ConA (3 μg/ml from Sigma-Aldrich) stimulated cultures were
used as positive control. All samples were analysed in triplicate. After
incubation at 37 °C and 5% CO2 for 24 h, PBMCs were discarded and
secondary IFN-γ antibody and streptavidin was added according to
manufacturer’s instruction. Spot development was stopped by washing
plates under tap water. The number of specific IFN-γ SCs, as determined
using an Immunospot® S4 Analyzer (Cellular Technology Ltd.), were
calculated as the average number of spots in the triplicate PBMC cul-
tures stimulated with virus minus the average number of spots in the
triplicate PBMC cultures exposed to culture medium only (non-specific
response or background).
2.10. Cytokine production measured by multiplex assay
Protein concentrations of IFN-α, TNF, IL-4 and IL-6 were measured
in the serum at 3 days after challenge. A custom-designed multiplex
Cytometric Bead Array (PorcineProcartaplex®; eBioscience) was used
according to the manufacturer’s instructions and read on a Luminex
machine (Luminex®200™). Cytokine concentrations were determined
using xPONENT® software. The detection limits of the cytokines were
0.72 pg/ml (IFN-α), 7.57 pg/ml (TNF), 1.55 pg/ml (IL-4) and 6.32 pg/
ml (IL-6), respectively.
2.11. PRRSV titers in serum measured by virus titration
Virus titers in serum were determined by virus titration on PAM,
obtained from 3 to 5 week old piglets from a PRRSV and PCV2 -free
herd in the Netherlands. The PAM were cultured in 24-well plates
(Greiner) at a concentration of 5× 105 cells/well in 1ml RPMI 1640
medium (Gibco®) supplemented with 10% FBS and 1% Penicillin-
Streptomycin (Gibco®). 10-fold dilution series of the serum samples
(four dilutions for each sample) were inoculated to the PAM (250 ųl)
and plates were incubated at 37 °C in a 5% CO2 humidified atmosphere.
After 3 days, the monolayers were washed in 0.15M NaCl solution,
dried and frozen. The monolayers were stained by IPMA to visualize
infection in the cells (van der Linden et al., 2003) using a 1:500 dilution
of the monoclonal antibody SDOW17-A (Rural Technologies) against
the nucleocapsid protein of PRRSV. Virus titers were calculated as
TCID50 as described by (Reed and Muench, 1938). The detection limit
of the virus titration was 1.0 log10TCID50/ ml. To check the sensitivity
of the PAM, all cell batches were assessed in the virus titrations with a
PRRSV stock (07V063) with a known virus titer.
2.12. Pathology
A complete necropsy was performed on all pigs. An ECVP board-
certified veterinary pathologist (SV) performed the macroscopic ex-
amination of the lung lesions. Macroscopic (or gross) lung lesions were
scored to estimate the percentage of affected lung tissue by pneumonia
according to (Halbur et al., 1995). For histology, samples were taken
from three predefined locations of the right lung: anterior lobe, middle
lobe and caudal lobe. Tissues were fixed in 4% neutral-buffered for-
maldehyde and routinely processed and embedded in paraffin. Con-
secutive 4 ųm thick sections were cut and stained with hematoxylin and
eosin (H&E).
H&E stained slides were analysed semi-quantitively in a “blinded”
manner by the same veterinary pathologist. The lung histology was
scored according to (Weesendorp et al., 2014) with slight modifica-
tions. Briefly, the three lung sections of the right lobe were scored for
the presence of a perivascular and peribronchiolar inflammatory in-
filtrate from 0 (no findings) to 5 (extended manifestation) and for the
alveolar wall infiltrate (0–5). To compare the histological findings be-
tween the groups, the perivascular and peribronchiolar scores of the
three sections per lung were added to an overall score, which could add
up to a maximum of 30.
2.13. Statistical analysis
Data were analysed using SPSS Statistics version 23. The distribu-
tion of the data was explored with the descriptive statistics. Data with
an overall normal distribution (ELISA and virus titration; Figs. 3 and 6,
respectively) were analysed with a one-way ANOVA followed by a post-
hoc Dunnett test (2-sided) using non-vaccinated animals and O/W
control group as reference groups. Non-parametric data (skin changes,
ELISpot, cytokines, an lung pathology; Figs. 2, 4, 5 and 7, respectively)
were analysed with a Kruskal-Wallis test followed by a post-hoc Mann-
Whitney U test for multiple comparisons. Association analysis was
performed with a Pearson correlation test (2-tailed). P- values less than
0.05 were considered statistical significant (*p < 0.05).
3. Results
3.1. Vaccine safety and challenge reaction
None of the vaccines induced any systemic adverse effects, such as
raise in body temperature, loss of appetite and activity or reduced
weight gain (data not shown). However, after application of TLRa and
iPRRSV in DMN patches, a transient local reaction was observed in
some animals, characterized by a variable local redness and swelling of
the skin graded from 0 (no change) to 3 (swelling and redness of the
skin) (Fig. 2A). The skiTLR7/8a group showed significantly more skin
reactions than skiTLR1/2a or 9a group (Fig. 2B and C) up to 2 days after
primary and 1 day after the booster immunization. There was no dif-
ference in severity between the prime and booster vaccination. All of
the local skin reactions disappeared within 4 days post vaccination. No
local reaction was observed after i.m. administration.
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Following challenge, none of the pigs in any of the study groups
exhibited PRRSV-related clinical signs or raise in body temperature.
Additionally, there was no significant difference in weight or weight
gain between the groups (results not shown).
3.2. PRRSV specific IgG antibody response
PRRSV-specific IgG antibodies were measured in the serum to de-
termine the humoral immune response. After booster vaccination (D35)
only the O/W control group showed a detectable PRRSV antibody re-
sponse (in 4 of the 6 animals) (Fig. 3A and B), while none of the animals
in the experimental TLRa groups were able to develop a specific anti-
body response after booster vaccination.
From eight days after challenge (D57 or 8 days post infection (dpi))
the imTLR1/2a, 7/8a and 9a groups showed a specific antibody re-
sponse at a comparable level to the O/W-control group (anamnestic
antibody response) with no significant difference between the different
TLRa groups (Fig. 3A). On D57 and D59 (8 and 10 dpi) the skiTLRa
groups showed a significantly lower antibody response compared to the
O/W control group (Fig. 3B). The skiTLRa groups developed a specific
antibody response from 14 dpi (D63) in nearly all animals, with no
significant difference between the TLRa groups.
3.3. T-cell IFN-γ response
After prime and booster vaccination the cellular immune response
Fig. 2. Skin reaction after dissolving microneedle (DMN) patch application with different Toll-like receptor (TLR) agonists. (A) Examples of grading of skin changes
(grade 1–3) based on redness and swelling of skin; normal skin (grade 0) is visible around the skin changes (B) Skin reaction overview from day 1 till day 4 after
prime vaccination (P) and after booster vaccination (C). Each bar represents the median of a group of 6 animals with the 95% CI. (*p < 0.05 compared to other
groups).
Fig. 3. Kinetics of PRRSV specific antibody response after booster vaccination. PRRSV antibody titers from booster vaccination (D28) till the end of the study
determined by ELISA. (A) i.m. vaccinated Toll-like receptor agonist (imTLRa) groups compared to non-vaccinated (NV) group and oil-in-water group control (O/W
con); (B) skin vaccinated skiTLRa groups compared to NV and O/W con groups; “C” indicates challenge at D49; The dotted line marks the detection limit for the
ELISA; Each data points represents the average of 6 animals ± S.D. “a” indicates a significant difference (*p<0.05) between the O/W con group and the imTLRa/
skiTLRa/ NV groups; “b” indicates a significant difference between the NV group and the imTLRa/ O/W con groups; “c” indicates a significant difference between the
O/W con group and the skiTLRa/ NV groups.
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was evaluated as number of IFN-γ SCs in the PBMCs after homologous
in vitro re-stimulation with the challenge strain. Overall, in all groups
there was a large individual variation between the animals in number of
IFN-γ SCs in non-stimulated and PRRSV stimulated samples. A large
number of non-stimulated control samples contained IFN-γ SCs, in-
dicating a non-antigen-specific IFN-γ production. Only after booster
vaccination (D42) the imTLR9a group showed significantly more non-
specific IFN-γ spots compared to the NV animals (Fig. 4A), additionally
this was observed as a trend, albeit not significant (0.05 < p < 0.10)
in the O/W control group compared to the NV animals. This increased
non-specific response compared to the NV group was not detectable in
the skiTLR9a group, TLR1/2a and 7/8a experimental groups of either
delivery routes.
There was no detectable antigen-specific cellular immune response
on D21 (3 weeks after prime vaccination) as PBMCs produced no spe-
cifically induced IFN-γ SCs (results not shown). On D42 (2 weeks after
booster vaccination) only in the O/W control group, 3 of the 6 animals
showed an increase in IFN-γ SCs (Fig. 4B) compared to the non-sti-
mulated control samples (p= 0.094), albeit not significant. None of the
animals in the experimental TLRa groups showed a significant increase
in IFN-γ SCs compared to the control samples.
3.4. Serum cytokines 4 days after challenge
To assess the influence of vaccination on the host response to viral
challenge the serum IFN-α (anti-viral cytokine), IL-4 (Th2-type cyto-
kine) levels and TNF and IL-6 levels (pro-inflammatory cytokines) were
analysed 3 days after challenge. All animals showed a detectable IFN-α
response with no significant difference between the groups (Fig. 5A).
The O/W control group showed significant increased IL-4 level com-
pared to the NV group with no significant difference between the two
administration routes (Fig. 5B).
The median levels and number of animals producing the pro-in-
flammatory cytokines TNF and IL-6 were highest in the skiTLR7/8a
group (Fig. 5C and D). TNF and IL-6 were equivalent to the non-vac-
cinated groups in all other groups. However, no significant differences
in TNF and IL-6 between groups were detected.
3.5. Viremia in serum
PRRSV 07V063 was not detected in the serum before challenge. At
D52 (3 dpi) PRRSV was detected in the serum of 92% of the animals
and at 5 dpi all animals were viremic. At D54 (5dpi) the virus titer of
only the skiTLR9a group was significantly lower than the NV group
(Fig. 6A), this reduction of viremia was not observed for other time
points in this group. At D63 (14 dpi) the O/W control and imTLR9a
group showed a significantly lower virus titer compared to the NV
animals (Fig. 6A and B); this decline was not observed in the other
experimental TLRa groups. The imTLR9a group showed as well a sig-
nificantly lower virus titer at 8 and 10 dpi.
The area under the curve (AUC) value was significantly lower for
the imTLR9a and O/W control group compared to the NV animals
(Fig. 6C), the other experimental TLRa groups did not show this de-
cline.
3.6. Pathology
There were no or minimal gross pathological changes in the lungs
21 days after challenge in all groups. The O/W control group did not
show any macroscopic changes in the lungs. In the other groups, in-
dividual scores ranged from 0% to 4% of affected lung surface (Fig. 7A).
There was no significant difference in lung histopathology between the
groups (Fig. 7B, C and D). The gross lesions were predominantly located
in the cranial and the middle lobe and were characterized by multifocal,
irregular, slightly sunken red to tan areas. The lungs of all pigs dis-
played mild to moderate histopathological changes, although the gross
changes were not evident. Compared to normal lung tissue histology of
a pig with the same age and genetic background (Fig. 7E), we observed
Fig. 4. PRRSV specific T-cell IFN-γ response two weeks after booster vaccination. Number of IFN-γ secreting cells (SC) after PBMC stimulation for 24 h with PBS (non-
stimulated) or PRRSV(07V063). Response of non-vaccinated (NV) group and oil-in-water control (O/W con) group compared to the i.m. vaccinated Toll-like receptor
agonists (imTLRa) groups and skin vaccinated skiTLRa groups measured two weeks after booster vaccination. Each symbol represents one animal (mean of triplicate
wells) and the median of the group set (n=6) is shown as a line; (A) Number IFN-γ SCs in non-stimulated ( background) and PRRSV stimulated samples ( ); (B) Net
IFN-γ SCs with background subtracted from stimulated samples; “a” indicates a significant difference (*p < 0.05) between non-stimulated samples of NV group and
imTLR9a group.
Fig. 5. Serum cytokine concentrations 3 days after PRRSV challenge. Serum
cytokines (pg/ml) in non-vaccinated (NV) group and oil-in-water control (O/W
con) group compared to the experimental i.m. vaccinated Toll-like receptor
agonist (imTLRa) groups and skin vaccinated skiTLRa groups for IFN-α (A), IL-4
(B), TNF (C) and IL-6 (D). Each symbol represents one animal and the median is
shown for the data set (n=5); (*p < 0.05).
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an interstitial pneumonia characterized by a mononuclear infiltrate of
mainly macrophages and lymphocytes in the alveolar septa and around
the blood vessels and bronchi and bronchioles (Fig. 7F and G). Also,
dispersed the alveolar lumina contained a similar mononuclear in-
filtrate, which was occasionally admixed with cellular debris.
3.7. Association between specific humoral and cellular immune response
and viral clearance
The time-points with the most prominent immune response (hu-
moral D35 and D57; cellular D42) and the time-point with the most
significant reduction of vireamie (D63) were used to investigate the
association between specific immune response and viral clearance. This
association between immunogenicity and efficacy was independent of
the vaccine adjuvant and administration route (all animal were in-
cluded, as well the NV group). There was a significant association of the
humoral immune response one week after booster vaccination (D35)
and one week after challenge (D57) with the cellular immune response
two weeks after booster vaccination (D42) (Fig. 8A and B). However, no
significant association was found between the viral clearance (D63) and
the specific humoral or cellular immune response (Fig. 8C and D).
4. Discussion
PRRSV is an important pathogen resulting in large scale health is-
sues in pigs with major economic impact, therefore development of
effective inactivated vaccines is highly desirable. Inadequate specific
immune responses, especially cell-mediated responses, are often
Fig. 6. Clearance of PRRSV in serum after challenge. Virus titers in serum (log10 TCID50/ml) determined by virus titration. (A) serum virus titers of i.m. vaccinated
Toll-like receptor (imTLRa) groups compared to non-vaccinated (NV) group and oil-in-water control (O/W con) group (B); serum virus titers of skin vaccinated
skiTLRa groups compared to non-NV group and O/W con group. Each data point represents the average of 6 animals ± S.D. The dotted line marks the detection limit
for virus titration; (C) Area under the curve (AUC) calculated for the whole group with the S.D. “a” indicates a significant difference (*p < 0.05) between imTLR9a
group and NV group; “b” between O/W con group and NV group and “c” between the skiTLR9a group and the NV group.
Fig. 7. PRRSV lung pathology 21 days after challenge. Lung tissue of non-vaccinated (NV) group and oil-in-water control (O/W con) group compared to the
experimental i.m. vaccinated Toll-like receptor agonist (imTLRa) groups and skin vaccinated skiTLRa groups. (A) The extension of gross lung lesions calculated as
proportion of total lung area; (B) Histologic lesions evaluated in the left cranial, medial and caudal lung lobe for infiltrate of mononuclear inflammatory cells in
alveolar walls (score 0–5 for each lobe), (C) and around blood vessels, bronchi and bronchioli (score 0–5 for each lobe) (D) combined to an overall histology score
(score 0–30); Each symbol represents one animal and the median is shown for the data set (n= 6). (E) Normal lung tissue histology of a control pig with the same
background and age (Haematoxylin and Eosin (H&E) stain; magnification 200x); (B) interstitial pneumonia 21 days after PRRSV infection with a significant
mononuclear infiltrate of mainly macrophages and lymphocytes around blood vessels and bronchi and bronchiole (arrow) (magnificantion 200x); (C) alveolar walls
are thickened by the same type of inflammatory cells (arrowhead) (magnification 400x).
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described for iPRRSV vaccines as a cause for limited protective efficacy
(Charerntantanakul, 2009; Geldhof et al., 2012; Renukaradhya et al.,
2015; Vanhee et al., 2009). TLRa activity links the innate and adaptive
immune response by activation of APCs and has a potency to enhance
cell-mediated responses and therefore could be a suitable method to
improve the efficacy of iPRRSV vaccines. Three different TLRa were
selected based on porcine in vitro study results (Auray et al., 2016;
Vreman et al., 2018) and this selection was supported by positive im-
munogenicity results from in vivo studies with inactivated vaccines in
pigs, mice and humans (Basto and Leitao, 2014; Linghua et al., 2007;
Zhang et al., 2013). The skin, which harbours a large number of APCs,
was included as administration route to explore the potency of the
different TLRa to a broader extent. Here, we examined the adjuvant
potency of TLR1/2a (Pam3Cys), TLR7/8a (R848) or TLR9 (CpG ODN)
to increase the iPRRSV vaccine response compared to an established O/
W control adjuvant.
We found that none of the TLRa was able to induce a detecable
specific immune response after booster vaccination for either delivery
routes. However, the imTLR9a showed reduction of vireamia, in-
dicating efficacy for CpG ODN as an injected adjuvant. As we only
observed a reduction of the viremia in the i.m. TLR9a group, we con-
sider that this result was most likely induced by the TLR9a as it was not
observed in the other experimental groups with TLRa and the iPRRSV
antigen. In the study design we did not include an iPRRSV only group as
we were interested in the vaccine formulation. We anticipated that the
iPRRSV antigen would be insufficient to show efficacy and/or an im-
mune response on its own, as it is common, that inactivated viral
vaccines are administered with an adjuvant.
Vaccine immunogenicity was measured by production of specific
IgG antibodies in the serum and specific IFN-γ+T-cell response after
vaccination. The ELISA showed only in the O/W control group a spe-
cific antibody response before challenge. These early antibodies often
appear within one week after booster vaccination, however there is
evidence that they play no significant role in PRRSV protection
(Labarque et al., 2000). Virus neutralizing antibodies appear at a later
time-point and their presence before challenge appears to correlate
with passive protection (Loving et al., 2015). In our study the experi-
mental TLRa groups lacked the induction of any measurable specific
antibody response before challenge, therefore the neutralizing anti-
bodies were not measured.
Three days after challenge the IL-4 serum level was measured as an
indicator of a Th2 or humoral immune response. Only in the O/W
control group 4 of the 5 animals showed a clear IL-4 response at 3 days
after challenge, supporting the specific antibody response after booster
vaccination in this group as observed in other PRRSV vaccine studies
(Chen et al., 2013; Wang et al., 2011). However, serum IL-4 is often
difficult to detect and the significance of this cytokine response for
porcine B-cell stimulation is under debate (Murtaugh et al., 2009). In
our study 2 of the 5 non- vaccinated animals also showed detectable IL-
4 levels and in addition the serum before challenge was not analysed.
Our study did not include an uninfected control group to measure
baseline cytokines as our aim was to investigate response differences
between vaccines. Therefore the IL-4 results should be interpreted with
caution as a reflection of the humoral response.
An enhanced specific IFN-γ response after booster vaccination and
IFN-α response after challenge could contribute to more effective
iPRRSV vaccines as insufficient T-cell responses and cytokine responses
most likely play a pivotal role in the delayed adaptive immune response
and clearance of PRRSV (Loving et al., 2015; van Reeth and Nauwynck,
2000). In our study the experimental TLR agonist groups did not en-
hance antigen-specific IFN-γ cell-mediated response after booster and
the anti-viral IFN-α response after challenge. However, an increase in
non-specific IFN-γ production in the imTLR9a group was noticed in the
ELISpot, which was most likely induced by activation of innate immune
cells. This non-specific Th1-skewed response was also observed in a
iPRRSV study with a different adjuvant system (Zuckermann et al.,
2007), which induced no protective immunity. Interestingly, in our
study only the imTLR9a group with this non-specific IFN-γ production
also showed a reduction of viremia. This suggests that this group was
able to induce a protective immune response, most likely supported by
the non-specific stimulation as measured in the ELISpot and the ana-
mnestic antibody response after challenge. We consider this anamnestic
antibody response suggestive for the added effect of the TLR agonist,
although an iPRRSV only vaccination group was not included and we
cannot fully exclude the contribution of iPRRSV antigen on its own.
Besides reduction of viremia, vaccine efficacy was assessed after
challenge by reduction of both clinical signs and lung pathology. Within
6 days after challenge all animals were viremic. However, the PRRSV
challenge did not induce any clinical signs or fever in the non-vacci-
nated animals. This mild clinical course has been described before for
the 07V063 strain (Geldhof et al., 2012; Weesendorp et al., 2013). The
lung pathology was determined 21 days after challenge and the histo-
logic changes were generally mild to moderate and characteristic for
PRRSV infection (Weesendorp et al., 2014). This mild lung pathology
could be due to the time of necropsy (day 21 post-infection), as lung
lesions are most prominent at 7–10 days post infection (Halbur et al.,
1995). Overall, we can conclude that the reduction of the viremia in the
O/W control and imTLR9a group did not result in reduced lung pa-
thology compared to NV group at 21 days post-infection. However, we
cannot exclude that at an earlier time-point after infection there could
have been differences in lung pathology.
Skin delivery with DMN-patches did not influence the vaccine im-
munogenicity compared to the i.m route. However, the imTLRa groups
were able to induce an anamnestic antibody response after challenge,
which was lower in the skiTLRa groups and only the imTLR9a group
showed significant vaccine efficacy after challenge. We did observe a
transient, but significant reduction of viremia at 5 dpi in the skiTLR9a
group. However, lower viral titers were not detected at other time-
points after challenge and AUC for the skiTLR9a was not significantly
reduced compared to the NV group. We interpret this finding that an
immune response was induced in this group that was capable of re-
tarding early virus growth, however it was insufficient to protect the
Fig. 8. Association between PRRSV specific humoral and cellular immune response and viral clearance. Scatter plots of humoral immune response on D35 (one week
after booster vaccination) and D57 (one week after challenge) versus cellular immune response on D42 (two weeks after booster vaccination)(A and B); Scatter plots
of viral clearance on D63 (15 days after challenge) versus cellular and humoral immune response (C and D). All animals indepent of vaccination an administration
route, were included in this association.
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host over time from continued and increased virus proliferation. A
porcine influenza study with skin vaccination demonstrated as well that
TLR9a (CpG ODN) (Bernelin-Cottet et al., 2016) intradermally in pigs
promoted the antigen-specific Ab responses, significantly but quite
weakly. Overall, it is an interesting finding that TLR9a by both the i.m.
and skin routes demonstrated the strongest efficacy potential.
It is unknown why the skin route was not able to benefit from the
high number of accessible APCs in the skin to induce a comparable
immune response and vaccine efficacy as seen in the imTLRa groups.
One explanation could be a lower vaccine bioavailability by the skin
route due to partially inserted DMN. It is commonly appreciated in the
microneedle field that less than 100% of the cargo is delivered into skin;
some reports where antigen is coated onto silicon microneedles report
as little as 7% being delivered into skin (Crichton et al., 2010). A
change in patch design, whereby the DMN contain the vaccine and
adjuvant in the tips of the DMN only, compared to homogenous dis-
tribution throughout the length of the DMN could facilitate an in-
creased dose delivery in future studies.
Another route-dependent finding was the local skin redness in
skiTLR7a group, which was less prominent or absent in the skiTLR1/2a
and 9a groups. This skin reaction is a strong indication for overall
successful DMN-patch application and as well a side effect for topical
administration of TLR7a Resiquimod (R848) as observed in other stu-
dies (Hengge and Ruzicka, 2004; Meyer et al., 2013). These side effects
were considered negligible compared to the immunostimulatory prop-
erties (Sauder, 2000; van Aalst et al., 2018) of the TLR7/8a. In our
study this difference in local immune response between the different
TLR agonist did not result in a more prominent antigen-specific immune
response, as assessed by antibody ELISA or IFN-γ ELISpot or anamnestic
immune response after challenge. However, other specific immune re-
sponses, such as tissue-specific T and/or B memory or mucosal re-
sponses, which did not contribute to protection, may have been induced
but were not evaluated.
No correlation was observed between the immune responses that
were evaluated and protection against virus challenge. This indicates
that other immune responses, which were not evaluated, were re-
psonsible for efficacy. These responses could include non-antigen spe-
cific innate immunity that may have been still active 2 weeks after the
booster immunization and/or memory immune responses that were
quickly re-activated after challenge but not assessed in our assays.
Interestingly, we found in the serum of skiTLR7a group a trend for a
higher level for the pro-inflammatory cytokines TNF and IL-6, post-
challenge, which could be correlated to the skin reaction. Overall, the
two different delivery routes showed only post-challenge differences in
efficacy for TLR9a.
We anticipated that selected TLR agonists would have stimulated
the production of pro-inflammatory cytokines/chemokines and type I
IFNs supporting the development of an adaptive immune response in
combination with the iPRRSV antigen. TLR7a and TLR9a combined
with high pathogenic iPRRSV-2 antigen in a comparable setting
(Linghua et al., 2007; Zhang et al., 2013) although with a different
TLR7a, were able to enhance these specific immune responses and
showed enhanced protection after homologous challenge. PRRSV-1 and
PRRSV-2 are highly different strains (around 60% homologous at
genome level) (Van Doorsselaere et al., 2012) and the use of iPRRSV-1
antigen might have provoked that our selected TLRa-antigen combi-
nations were less successful. As well, we have to consider that the in-
nate immune response directly after vaccination was not evaluated and
it is unclear to what extent actual TLR activation occurred. We cannot
exclude that the dose of the different TLRa was not optimal for the i.m/
and or the skin vaccination. As especially for the patches, no previous
experiments have been performed and our reference dose for the dif-
ferent TLRa was based on different animal species and delivery routes
combined with the maximum dose which could be incorporated in the
DMN- patches. However, the O/W reference adjuvant was able to in-
duce a specific immune response with iPRRSV-1 in combination with
reduction of viremia. Possibly a different adjuvant system where dif-
ferent combinations of TLR agonists are combined with e.g. O/W ad-
juvant, liposomes (McKee and Marrack, 2017; Neeland et al., 2014) or
plasmids (Quan et al., 2010) could enhance the vaccine properties and
would be a direction for further research.
5. Conclusion
TLR 1/2a, 7/8a or 9a incorporated as adjuvants in iPRRSV 07V063
antigen based vaccine were unable to induce a measurable specific
immune response after booster vaccination and only the imTLR9a
group induced reduction of viremia after homologous challenge, sup-
ported by non-antigen-specific IFN-γ production after booster vaccina-
tion and an anamnestic antibody response after challenge. Further re-
search is needed with different adjuvant systems, dosing regimens and
combinations of TLR agonists and delivery routes to explore the po-
tentials of TLRa as adjuvant for porcine vaccines with a preference for
TLR9a.
Conflict of interest statement
None of the authors have any potential conflict of interest regarding
or related to this work.
Acknowledgments
The authors thank Artur Summerfield for his advice regarding ad-
juvant selection as partner of Horizon 2020 Programme. Ivan Trus and
Lisette Ruuls are acknowledged for their technical assistance. The an-
imal caretakers are thanked for collection of all samples and providing
optimal housing conditions for the pigs used in this experiment. Conor
O’Mahony at the Tyndall National Institute, UCC is acknowledged for
supplying PDMS moulds. This project has received funding from the
European Union’s Horizon 2020 Programme for research, technological
development and demonstration under the Grant Agreement
no.633184. This publication reflects the views only of the author, and
not the European Commission (EC). The EC is not liable for any use that
may be made of the information contained herein.
References
Akira, S., Takeda, K., 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499–511.
Auray, G., Keller, I., Python, S., Gerber, M., Bruggmann, R., Ruggli, N., Summerfield, A.,
2016. Characterization and transcriptomic analysis of porcine blood conventional
and plasmacytoid dendritic cells reveals striking species-specific differences. J.
Immunol. 197, 4791–4806.
Basto, A.P., Leitao, A., 2014. Targeting TLR2 for vaccine development. J Immunol Res.
2014, 619410.
Bernelin-Cottet, C., Deloizy, C., Stanek, O., Barc, C., Bouguyon, E., Urien, C., Boulesteix,
O., Pezant, J., Richard, C.A., Moudjou, M., Da Costa, B., Jouneau, L., Chevalier, C.,
Leclerc, C., Sebo, P., Bertho, N., Schwartz-Cornil, I., 2016. A universal influenza
vaccine can lead to disease exacerbation or viral control depending on delivery
strategies. Front. Immunol. 7, 641.
Brar, M.S., Shi, M., Murtaugh, M.P., Leung, F.C., 2015. Evolutionary diversification of
type 2 porcine reproductive and respiratory syndrome virus. J. Gen. Virol. 96,
1570–1580.
Charerntantanakul, W., 2009. Adjuvants for porcine reproductive and respiratory syn-
drome virus vaccines. Vet. Immunol. Immunopathol. 129, 1–13.
Chen, C., Li, J., Bi, Y., Yang, L., Meng, S., Zhou, Y., Jia, X., Meng, S., Sun, L., Liu, W.,
2013. Synthetic B- and T-cell epitope peptides of porcine reproductive and re-
spiratory syndrome virus with Gp96 as adjuvant induced humoral and cell-mediated
immunity. Vaccine 31, 1838–1847.
Crichton, M.L., Ansaldo, A., Chen, X., Prow, T.W., Fernando, G.J., Kendall, M.A., 2010.
The effect of strain rate on the precision of penetration of short densely-packed mi-
croprojection array patches coated with vaccine. Biomaterials 31, 4562–4572.
Diaz, I., Venteo, A., Rebollo, B., Martin-Valls, G.E., Simon-Grife, M., Sanz, A., Mateu, E.,
2012. Comparison of two commercial enzyme-linked immunosorbent assays for the
diagnosis of porcine reproductive and respiratory syndrome virus infection. J Vet.
Diagn. Invest. Inc. 24, 344–348.
Du, Y., Du, T., Shi, Y., Zhang, A., Zhang, C., Diao, Y., Jin, G., Zhou, E.M., 2016. Synthetic
Toll-like receptor 7 ligand inhibits porcine reproductive and respiratory syndrome
virus infection in primary porcine alveolar macrophages. Antiviral Res. 131, 9–18.
Eble, P.L., Weerdmeester, K., van Hemert-Kluitenberg, F., Dekker, A., 2009. Intradermal
S. Vreman, et al. Veterinary Immunology and Immunopathology 212 (2019) 27–37
35
vaccination of pigs against FMD with 1/10 dose results in comparable vaccine effi-
cacy as intramuscular vaccination with a full dose. Vaccine 27, 1272–1278.
Ferrari, L., Martelli, P., Saleri, R., De Angelis, E., Cavalli, V., Bresaola, M., Benetti, M.,
Borghetti, P., 2013. Lymphocyte activation as cytokine gene expression and secretion
is related to the porcine reproductive and respiratory syndrome virus (PRRSV) isolate
after in vitro homologous and heterologous recall of peripheral blood mononuclear
cells (PBMC) from pigs vaccinated and exposed to natural infection. Vet. Immunol.
Immunopathol. 151, 193–206.
Geldhof, M.F., Vanhee, M., Van Breedam, W., Van Doorsselaere, J., Karniychuk, U.U.,
Nauwynck, H.J., 2012. Comparison of the efficacy of autogenous inactivated porcine
reproductive and respiratory syndrome virus (PRRSV) vaccines with that of com-
mercial vaccines against homologous and heterologous challenges. BMC Vet. Res. 8,
182.
Halbur, P.G., Paul, P.S., Frey, M.L., Landgraf, J., Eernisse, K., Meng, X.J., Lum, M.A.,
Andrews, J.J., Rathje, J.A., 1995. Comparison of the pathogenicity of two US porcine
reproductive and respiratory syndrome virus isolates with that of the Lelystad virus.
Vet. Pathol. 32, 648–660.
Hengge, U.R., Ruzicka, T., 2004. Topical immunomodulation in dermatology: potential of
toll-like receptor agonists. Dermatol. Surg. 30, 1101–1112.
Kappes, M.A., Faaberg, K.S., 2015. PRRSV structure, replication and recombination:
origin of phenotype and genotype diversity. Virology 479–480, 475–486.
Karniychuk, U.U., Geldhof, M., Vanhee, M., Van Doorsselaere, J., Saveleva, T.A.,
Nauwynck, H.J., 2010. Pathogenesis and antigenic characterization of a new East
European subtype 3 porcine reproductive and respiratory syndrome virus isolate.
BMC Vet. Res. 6, 30.
King, A.M.Q., Lefkowitz, E.J., Mushegian, A.R., Adams, M.J., Dutilh, B.E., Gorbalenya,
A.E., Harrach, B., Harrison, R.L., Junglen, S., Knowles, N.J., Kropinski, A.M.,
Krupovic, M., Kuhn, J.H., Nibert, M.L., Rubino, L., Sabanadzovic, S., Sanfacon, H.,
Siddell, S.G., Simmonds, P., Varsani, A., Zerbini, F.M., Davison, A.J., 2018. Changes
to taxonomy and the International code of virus classification and nomenclature
ratified by the International committee on taxonomy of viruses. Arch. Virol 2018.
Knudsen, N.P., Olsen, A., Buonsanti, C., Follmann, F., Zhang, Y., Coler, R.N., Fox, C.B.,
Meinke, A., D’Oro, U., Casini, D., Bonci, A., Billeskov, R., De Gregorio, E., Rappuoli,
R., Harandi, A.M., Andersen, P., Agger, E.M., 2016. Different human vaccine ad-
juvants promote distinct antigen-independent immunological signatures tailored to
different pathogens. Sci. Rep. 6, 19570.
Krejci, J., Nechvatalova, K., Kudlackova, H., Leva, L., Bernardy, J., Toman, M., Faldyna,
M., 2013. Effects of adjuvants on the immune response of pigs after intradermal
administration of antigen. Res. Vet. Sci. 94, 73–76.
Labarque, G.G., Nauwynck, H.J., Van Reeth, K., Pensaert, M.B., 2000. Effect of cellular
changes and onset of humoral immunity on the replication of porcine reproductive
and respiratory syndrome virus in the lungs of pigs. J. Gen. Virol. 81, 1327–1334.
Le Luduec, J.B., Debeer, S., Piras, F., Andreoni, C., Boudet, F., Laurent, P., Kaiserlian, D.,
Dubois, B., 2016. Intradermal vaccination with un-adjuvanted sub-unit vaccines
triggers skin innate immunity and confers protective respiratory immunity in do-
mestic swine. Vaccine 34, 914–922.
Linghua, Z., Yong, G., Xingshan, T., Fengzhen, Z., 2006. Co-administration of porcine-
specific CpG oligodeoxynucleotide enhances the immune responses to pseudorabies
attenuated virus vaccine in newborn piglets in vivo. Dev. Comp. Immunol. 30,
589–596.
Linghua, Z., Xingshan, T., Fengzhen, Z., 2007. Vaccination with porcine reproductive and
respiratory syndrome killed virus vaccine and immunostimulatory oligodeox-
ynucleotides induces specific immunity in piglets. Vaccine 25, 1735–1742.
Loving, C.L., Osorio, F.A., Murtaugh, M.P., Zuckermann, F.A., 2015. Innate and adaptive
immunity against porcine reproductive and respiratory syndrome virus. Vet.
Immunol. Immunopathol. 167, 1–14.
Magiri, R.B., Lai, K., Chaffey, A.M., Wilson, H.L., Berry, W.E., Szafron, M.L., Mutwiri,
G.K., 2016. Response of immune response genes to adjuvants poly [di(sodium car-
boxylatoethylphenoxy)phosphazene] (PCEP), CpG oligodeoxynucleotide and emul-
sigen at intradermal injection site in pigs. Vet. Immunol. Immunopathol. 175, 57–63.
Mair, K.H., Koinig, H., Gerner, W., Hohne, A., Bretthauer, J., Kroll, J.J., Roof, M.B.,
Saalmuller, A., Stadler, K., Libanova, R., 2015. Carbopol improves the early cellular
immune responses induced by the modified-life vaccine ingelvac PRRS(R) MLV. Vet.
Microbiol. 176, 352–357.
Maisonneuve, C., Bertholet, S., Philpott, D.J., De Gregorio, E., 2014. Unleashing the po-
tential of NOD- and Toll-like agonists as vaccine adjuvants. PNAS 111, 12294–12299.
Marshall, S., Sahm, L.J., Moore, A.C., 2016. The success of microneedle-mediated vaccine
delivery into skin. Hum. Vaccin. Immunother 0.
Martelli, P., Saleri, R., Cavalli, V., De Angelis, E., Ferrari, L., Benetti, M., Ferrarini, G.,
Merialdi, G., Borghetti, P., 2014. Systemic and local immune response in pigs in-
tradermally and intramuscularly injected with inactivated mycoplasma hyopneu-
moniae vaccines. Vet. Microbiol. 168, 357–364.
McKay, P.F., King, D.F., Mann, J.F., Barinaga, G., Carter, D., Shattock, R.J., 2016. TLR4
and TLR7/8 adjuvant combinations generate different vaccine antigen-specific im-
mune outcomes in minipigs when administered via the ID or IN routes. PloS one 11,
e0148984.
McKee, A.S., Marrack, P., 2017. Old and new adjuvants. Curr. Opin. Immunol. 47, 44–51.
Meyer, T., Surber, C., French, L.E., Stockfleth, E., 2013. Resiquimod, a topical drug for
viral skin lesions and skin cancer. Expert Opin. Invest. Drugs 22, 149–159.
Mokhtar, H., Pedrera, M., Frossard, J.P., Biffar, L., Hammer, S.E., Kvisgaard, L.K., Larsen,
L.E., Stewart, G.R., Somavarapu, S., Steinbach, F., Graham, S.P., 2016. The Non-
structural protein 5 and matrix protein are antigenic targets of T cell immunity to
genotype 1 porcine reproductive and respiratory syndrome viruses. Front. Immunol.
7, 40.
Murtaugh, M.P., Johnson, C.R., Xiao, Z., Scamurra, R.W., Zhou, Y., 2009. Species spe-
cialization in cytokine biology: is interleukin-4 central to the T(H)1-T(H)2 paradigm
in swine? Dev. Comp. Immunol. 33, 344–352.
Nan, Y., Wu, C., Gu, G., Sun, W., Zhang, Y.J., Zhou, E.M., 2017. Improved vaccine against
PRRSV: current progress and future perspective. Front. Microbiol. 8, 1635.
Nathues, H., Alarcon, P., Rushton, J., Jolie, R., Fiebig, K., Jimenez, M., Geurts, V.,
Nathues, C., 2017. Cost of porcine reproductive and respiratory syndrome virus at
individual farm level - an economic disease model. Prev. Vet. Med. 142, 16–29.
Neeland, M.R., Elhay, M.J., Nathanielsz, J., Meeusen, E.N., de Veer, M.J., 2014.
Incorporation of CpG into a liposomal vaccine formulation increases the maturation
of antigen-loaded dendritic cells and monocytes to improve local and systemic im-
munity. J. Immunol. 192, 3666–3675.
Nelsen, C.J., Murtaugh, M.P., Faaberg, K.S., 1999. Porcine reproductive and respiratory
syndrome virus comparison: divergent evolution on two continents. J. Virol. 73,
270–280.
Nieuwenhuis, N., Duinhof, T.F., van Nes, A., 2012. Economic analysis of outbreaks of
porcine reproductive and respiratory syndrome virus in nine sow herds. Vet. Rec.
170, 225.
Ouyang, K., Hiremath, J., Binjawadagi, B., Shyu, D.L., Dhakal, S., Arcos, J., Schleappi, R.,
Holman, L., Roof, M., Torrelles, J.B., Renukaradhya, G.J., 2016. Comparative analysis
of routes of immunization of a live porcine reproductive and respiratory syndrome
virus (PRRSV) vaccine in a heterologous virus challenge study. Vet. Res. 47, 45.
Quan, Z., Qin, Z.G., Zhen, W., Feng, X.Z., Hong, J., Fei, Z.H., 2010. Plasmid containing
CpG oligodeoxynucleotides can augment the immune responses of pigs immunized
with porcine reproductive and respiratory syndrome killed virus vaccine. Vet.
Immunol. Immunopathol. 136, 257–264.
Reed, L., Muench, H., 1938. A simple method of estimating fifty percent endpoints. Am. J.
Hyg. 27, 493–497.
Renukaradhya, G.J., Meng, X.J., Calvert, J.G., Roof, M., Lager, K.M., 2015. Inactivated
and subunit vaccines against porcine reproductive and respiratory syndrome: current
status and future direction. Vaccine 33, 3065–3072.
Salabert, N., Todorova, B., Martinon, F., Boisgard, R., Zurawski, G., Zurawski, S.,
Dereuddre-Bosquet, N., Cosma, A., Kortulewski, T., Banchereau, J., Levy, Y., Le
Grand, R., Chapon, C., 2016. Intradermal injection of an anti-langerin-HIVGag fusion
vaccine targets epidermal langerhans cells in nonhuman primates and can be tracked
in vivo. Eur. J. Immunol. 46, 689–700.
Sauder, D.N., 2000. Immunomodulatory and pharmacologic properties of imiquimod. J.
Am. Acad. Dermatol. 43, S6–11.
Scheiermann, J., Klinman, D.M., 2014. Clinical evaluation of CpG oligonucleotides as
adjuvants for vaccines targeting infectious diseases and cancer. Vaccine 32,
6377–6389.
Shakya, N., Sane, S.A., Shankar, S., Gupta, S., 2011. Effect of Pam3Cys induced protection
on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis.
Peptides 32, 2131–2133.
Stadejek, T., Oleksiewicz, M.B., Scherbakov, A.V., Timina, A.M., Krabbe, J.S., Chabros, K.,
Potapchuk, D., 2008. Definition of subtypes in the European genotype of porcine
reproductive and respiratory syndrome virus: nucleocapsid characteristics and geo-
graphical distribution in Europe. Arch. Virol 153, 1479–1488.
Stadejek, T., Stankevicius, A., Murtaugh, M.P., Oleksiewicz, M.B., 2013. Molecular evo-
lution of PRRSV in Europe: current state of play. Vet. Microbiol. 165, 21–28.
Steinhagen, F., Kinjo, T., Bode, C., Klinman, D.M., 2011. TLR-based immune adjuvants.
Vaccine 29, 3341–3355.
Takeda, K., Akira, S., 2005. Toll-like receptors in innate immunity. Int. Immunol. 17,
1–14.
Toussi, D.N., Massari, P., 2014. Immune adjuvant effect of molecularly-defined Toll-like
receptor ligands. Vaccines 2, 323–353.
Uenishi, H., Shinkai, H., 2009. Porcine Toll-like receptors: the front line of pathogen
monitoring and possible implications for disease resistance. Dev. Comp. Immunol. 33,
353–361.
van Aalst, S., Jansen, M.A.A., Ludwig, I.S., van der Zee, R., van Eden, W., Broere, F., 2018.
Routing dependent immune responses after experimental R848-adjuvated vaccina-
tion. Vaccine 36, 1405–1413.
Van Breedam, W., Costers, S., Vanhee, M., Gagnon, C.A., Rodriguez-Gomez, I.M., Geldhof,
M., Verbeeck, M., Van Doorsselaere, J., Karniychuk, U., Nauwynck, H.J., 2011.
Porcine reproductive and respiratory syndrome virus (PRRSV)-specific mAbs: sup-
porting diagnostics and providing new insights into the antigenic properties of the
virus. Vet. Immunol. Immunopathol. 141, 246–257.
van der Linden, I.F., Voermans, J.J., van der Linde-Bril, E.M., Bianchi, A.T., Steverink,
P.J., 2003. Virological kinetics and immunological responses to a porcine re-
productive and respiratory syndrome virus infection of pigs at different ages. Vaccine
21, 1952–1957.
Van der Stede, Y., Verdonck, F., Vancaeneghem, S., Cox, E., Goddeeris, B.M., 2002. CpG-
oligodinucleotides as an effective adjuvant in pigs for intramuscular immunizations.
Vet. Immunol. Immunopathol. 86, 31–41.
Van Doorsselaere, J., Geldhof, M., Nauwynck, H.J., Delputte, P.L., 2011. Characterization
of a circulating PRRSV strain by means of random PCR cloning and full genome
sequencing. Virol. J. 8, 160.
Van Doorsselaere, J., Brar, M.S., Shi, M., Karniychuk, U., Leung, F.C., Nauwynck, H.J.,
2012. Complete genome characterization of a East European Type 1 subtype 3 por-
cine reproductive and respiratory syndrome virus. Virus Genes 44, 51–54.
van Reeth, K., Nauwynck, H., 2000. Proinflammatory cytokines and viral respiratory
disease in pigs. Vet. Res. 31, 187–213.
Vanhee, M., Delputte, P.L., Delrue, I., Geldhof, M.F., Nauwynck, H.J., 2009. Development
of an experimental inactivated PRRSV vaccine that induces virus-neutralizing anti-
bodies. Vet. Res. 40, 63.
Vrdoljak, A., Allen, E.A., Ferrara, F., Temperton, N.J., Crean, A.M., Moore, A.C., 2016.
Induction of broad immunity by thermostabilised vaccines incorporated in dis-
solvable microneedles using novel fabrication methods. J. Control Release 225,
S. Vreman, et al. Veterinary Immunology and Immunopathology 212 (2019) 27–37
36
192–204.
Vreman, S., Auray, G., Savelkoul, H.F.J., Rebel, A., Summerfield, A., Stockhofe-
Zurwieden, N., 2018. Neonatal porcine blood derived dendritic cells subsets show
activation after TLR2 or TLR9 stimulation. Dev. Comp. Immunol. 84, 361–370.
Wang, G., Song, T., Yu, Y., Liu, Y., Shi, W., Wang, S., Rong, F., Dong, J., Liu, H., Cai, X.,
Zhou, E.M., 2011. Immune responses in piglets infected with highly pathogenic
porcine reproductive and respiratory syndrome virus. Vet. Immunol. Immunopathol.
142, 170–178.
Weesendorp, E., Morgan, S., Stockhofe-Zurwieden, N., Popma-De Graaf, D.J., Graham,
S.P., Rebel, J.M., 2013. Comparative analysis of immune responses following ex-
perimental infection of pigs with European porcine reproductive and respiratory
syndrome virus strains of differing virulence. Vet. Microbiol. 163, 1–12.
Weesendorp, E., Rebel, J.M., Popma-De Graaf, D.J., Fijten, H.P., Stockhofe-Zurwieden, N.,
2014. Lung pathogenicity of European genotype 3 strain porcine reproductive and
respiratory syndrome virus (PRRSV) differs from that of subtype 1 strains. Vet.
Microbiol. 174, 127–138.
Weldon, W.C., Zarnitsyn, V.G., Esser, E.S., Taherbhai, M.T., Koutsonanos, D.G.,
Vassilieva, E.V., Skountzou, I., Prausnitz, M.R., Compans, R.W., 2012. Effect of ad-
juvants on responses to skin immunization by microneedles coated with influenza
subunit vaccine. PloS one 7, e41501.
Zhang, L., Bai, J., Liu, J., Wang, X., Li, Y., Jiang, P., 2013. Toll-like receptor ligands
enhance the protective effects of vaccination against porcine reproductive and re-
spiratory syndrome virus in swine. Vet. Microbiol. 164, 253–260.
Zhang, L., Wang, W., Wang, S., 2015. Effect of vaccine administration modality on im-
munogenicity and efficacy. Expert Rev. Vaccines. 14, 1509–1523.
Zuckermann, F.A., Garcia, E.A., Luque, I.D., Christopher-Hennings, J., Doster, A., Brito,
M., Osorio, F., 2007. Assessment of the efficacy of commercial porcine reproductive
and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic
response, frequency of gamma-IFN-producing cells and virological parameters of
protection upon challenge. Vet. Microbiol. 123, 69–85.
S. Vreman, et al. Veterinary Immunology and Immunopathology 212 (2019) 27–37
37
